AD01 Follow up Extension Visit

Observational Follow-up Extension Study-visit to Evaluate Long-term Safety and Tolerability of Immunization With AFFITOPE AD01 Applied During AFFiRiS001 in Patients With Alzheimer's Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01225809

Enrollment

Registered

2010-10-21

Start date

2010-09-30

Completion date

2011-01-31

Last updated

2011-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer´s Disease

Keywords

AD01 follow-up extension

Brief summary

Patients who were vaccinated with AFFITOPE AD01 during AFFiRiS001 will undergo a long-term follow-up period to get more information regarding the safety profile of AFFITOPE AD01.

Interventions

None listed

Study design

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Written informed consent signed and dated by the patient or the patient's legal representative and the caregiver. * Patients having participated in AFFiRiS 001 and AFF003 and having received ≥1 vaccination with AFFITOPE AD01 * Availability of a partner/caregiver knowing the patient

Exclusion criteria

* Patients having received no vaccination with AFFITOPE AD01 * History of questionable compliance to visit schedule

Design outcomes

Primary

Measure	Time frame	Description
Long term tolerability and safety of AFFITOPE AD01	One year.	retrospective assessment of safety data

Countries

Austria

Outcome results